Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...